Pentagamavunone-1 targets excessive MYCN/NCYM expression mediated by mitotic arrest to suppress hepatocellular carcinoma proliferation

Novitasari, Dhania and Nakamae, Ikuko and Yoneda-Kato, Noriko and Meiyanto, Edy and Kato, Jun-Ya (2025) Pentagamavunone-1 targets excessive MYCN/NCYM expression mediated by mitotic arrest to suppress hepatocellular carcinoma proliferation. Cancer Gene Therapy, 32 (11). 1233 - 1244. ISSN 09291903

[thumbnail of s41417-025-00956-y.pdf] Text
s41417-025-00956-y.pdf - Published Version
Restricted to Registered users only

Download (3MB) | Request a copy

Abstract

Hepatocellular carcinoma (HCC) is a common liver cancer often diagnosed at an advanced stage. While chemotherapies such as sorafenib is effective for some patients, others show poor responses, necessitating new treatments. Overexpression of MYCN/NCYM was recently shown to contribute to the development of HCC. This study investigated the effects of Pentagamavunone-1 (PGV-1), a curcumin analog with strong antiproliferative properties, on HCC cells expressing MYCN/NCYM. PGV-1 was more effective than curcumin and sorafenib in inhibiting HCC cell proliferation by inducing mitotic arrest, oxidative stress, and senescence. In MYCN-positive JHH-7 cells, PGV-1 treatment increased phosphorylation of aurora A, cyclin B1, and PLK1. PGV-1 also suppressed MYCN/NCYM transcription and destabilized MYCN protein by inducing phosphorylation at Ser54 and Thr58. In a xenograft model, PGV-1 significantly reduced tumor formation and growth. These findings highlight PGV-1s potential as a targeted therapy for MYCN-overexpressing HCC, warranting further development. © The Author(s), under exclusive licence to Springer Nature America, Inc. 2025.

Item Type: Article
Additional Information: Cited by: 0
Uncontrolled Keywords: Animals; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Gene Expression Regulation, Neoplastic; Humans; Liver Neoplasms; Mice; Mitosis; N-Myc Proto-Oncogene Protein; Phosphorylation; Xenograft Model Antitumor Assays; antineoplastic agent; aurora A kinase; curcumin; cyclin B1; polo like kinase 1; serine; sorafenib; threonine; MYCN protein, human; N Myc proto oncogene protein; animal experiment; animal model; animal tissue; antiproliferative activity; Article; cancer growth; carcinogenesis; cell aging; cell proliferation; controlled study; drug efficacy; enzyme phosphorylation; female; gene expression; Hep-G2 cell line; Huh-7 cell line; JHH-7 cell line; liver cell carcinoma; mitosis inhibition; mouse; nonhuman; oxidative stress; protein phosphorylation; tumor xenograft; animal; drug effect; drug screening; drug therapy; gene expression regulation; genetics; human; liver cell carcinoma; liver tumor; metabolism; mitosis; pathology; phosphorylation; tumor cell line
Subjects: R Medicine > RM Therapeutics. Pharmacology
R Medicine > RS Pharmacy and materia medica
Divisions: Faculty of Pharmacy
Depositing User: Muh Aly Mubarok
Date Deposited: 27 Oct 2026 02:50
Last Modified: 27 Oct 2026 02:50
URI: https://ir.lib.ugm.ac.id/id/eprint/30264

Actions (login required)

View Item
View Item